USPH
U.S. Physical Therapy, Inc.
NYSEUSDEQUITY
Healthcare
DELAYED
Last price
78.21
▲ 0.67 (0.86%)
MARKET · —
Price
Open
78.00
Prev close
77.54
Day high
79.68
Day low
77.23
Volume
124.24K
Market cap
$1.17B
P/E (TTM)
460.06
52W range
58.19 – 93.50
Trailing performance
Returnvs SPY
1W
-3.73%
-2.4%
1M
+7.18%
+3.5%
3M
+24.44%
+21.3%
6M
-8.09%
-19.2%
YTD
+0.15%
-12.1%
1Y
-7.01%
-27.0%
3Y
-22.72%
-96.9%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$1.17B
Enterprise value$1.84B
Revenue (TTM)$804.27M
Gross profit$172.65M
EBITDA$102.01M
Net income$2.66M
EPS (TTM)$0.17
Free cash flow$41.29M
Total cash$26.26M
Total debt$385.79M
Book value / share$31.51
Shares outstanding14.92M
Float14.54M
Short % of float8.87%
Dividend yield2.35%
Beta (5Y)1.13
Valuation & profitability ratios
Trailing P/E460.06
Forward P/E23.12
PEG ratio2.84
Price / sales—
Price / book2.48
EV / revenue2.29
EV / EBITDA18.08
Gross margin21.47%
Operating margin11.13%
Profit margin4.01%
Return on equity6.51%
Return on assets4.10%
Debt / equity50.32
Current ratio1.27
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | $780.99M | $671.35M | $604.80M | $553.14M |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | $39.58M | $31.42M | $28.24M | $32.16M |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | $39.58M | $31.42M | $28.24M | $32.16M |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 0.84 | 0.75 | -11.1% |
| Mar 2026 | 0.52 | 0.46 | -11.0% |
| Dec 2025 | 0.67 | 0.67 | -0.6% |
| Sep 2025 | 0.66 | 0.66 | +0.1% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 0.75 | 7 | $214.01M | +8.6% |
| Next quarter | 0.91 | 7 | $219.94M | +8.5% |
| Current year | 2.89 | 6 | $846.20M | +8.4% |
| Next year | 3.38 | 7 | $908.46M | +7.4% |
Analyst targets & ownership
Mean target$95.00
High target$100.00
Low target$88.00
Implied upside21.47%
Analyst count6
ConsensusBUY
Strong buy / Buy4 / 2
Hold1
Sell / Strong sell0 / 0
Held by insiders2.51%
Held by institutions110.94%
Institutions holding323
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
+88.37K
Net buying
Buy transactions
16
93.84K shares
Sell transactions
3
5.47K shares
Net transactions
+19
Buys less sells
Sell : buy shares
0.1 : 1
Mixed
Insider-held shares
375.01K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jun 9, 26 | MINAN PETER FRANCIS Director |
BUY | 780 | $48.78K | Direct |
| May 19, 26 | MINAN PETER FRANCIS Director |
STOCK | 2.31K | $142.07K | Direct |
| May 19, 26 | MINAN PETER FRANCIS Director |
STOCK | 2.31K | $0 | Direct |
| May 19, 26 | GILMARTIN KATHLEEN A Director |
STOCK | 2.31K | $142.07K | Direct |
| May 19, 26 | GILMARTIN KATHLEEN A Director |
STOCK | 2.31K | $0 | Direct |
| May 19, 26 | HARRIS BERNARD A. JR Director |
STOCK | 2.31K | $142.07K | Direct |
| May 19, 26 | HARRIS BERNARD A. JR Director |
STOCK | 2.31K | $0 | Direct |
| May 19, 26 | MOTSENBOCKER ANNE Director |
STOCK | 2.31K | $142.07K | Direct |
| May 19, 26 | MOTSENBOCKER ANNE Director |
STOCK | 2.31K | $0 | Direct |
| May 19, 26 | SWANSON REGG E Director |
STOCK | 2.31K | $142.07K | Direct |
| May 19, 26 | SWANSON REGG E Director |
STOCK | 2.31K | $0 | Direct |
| Mar 11, 26 | REEVE GRAHAM D Chief Operating Officer |
SELL | 662 | $52.20K | Direct |
| Mar 9, 26 | REEVE GRAHAM D Chief Operating Officer |
SELL | 1.81K | $148.70K | Indirect |
| Mar 6, 26 | BINSTEIN RICHARD S General Counsel |
SELL | 3.00K | $244.92K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BINSTEIN RICHARD S |
General Counsel | 24.87K | Sale |
GILMARTIN KATHLEEN A |
Director | 27.09K | Stock Award(Grant) |
HARRIS BERNARD A. JR |
Director | 20.91K | Stock Award(Grant) |
HENDRICKSON CAREY P |
Chief Financial Officer | 37.81K | Stock Award(Grant) |
MOTSENBOCKER ANNE |
Director | 9.81K | Stock Award(Grant) |
READING CHRISTOPHER J |
Chief Executive Officer | 139.09K | Stock Award(Grant) |
REEVE GRAHAM D |
Chief Operating Officer | 30.08K | Sale |
SWANSON REGG E |
Director | 23.09K | Stock Award(Grant) |
TRIER CLAYTON K |
Director | 8.31K | Stock Award(Grant) |
WILLIAMS ERIC JOSEPH |
President | 40.33K | Stock Award(Grant) |
Moving averages & technicals
SMA 10
80.15
-2.42% from price
SMA 20
79.20
-1.25% from price
SMA 50
73.50
+6.40% from price
SMA 100
71.09
+10.02% from price
SMA 200
75.42
+3.69% from price
EMA 12
79.02
-1.03% from price
EMA 26
77.53
+0.88% from price
EMA 50
75.06
+4.20% from price
RSI (14)
52.5
Neutral
MACD (12,26,9)
1.50
Hist -0.60
ATR (14)
3.09
3.94% of price
Realised vol 30D
31.4%
Annualised
Bollinger upper
83.00
20, 2σ
Bollinger lower
75.40
20, 2σ
50 / 200 cross
Death
73.50 vs 75.42
Trend bias
Above 200
+3.69%
Risk profile
Beta vs SPY
0.67
Less volatile than market
Correlation to SPY
0.22
Largely independent
Realised vol 30D
31.4%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-36.7%
Peak to trough
Max drawdown 5Y
-54.7%
Peak to trough
ATR 14
3.09
3.94% of price
Beta (reported)
1.13
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
1.55
Put-heavy session
Put / call open interest
2.12
Positioning, not flow
Max pain
80.00
+2.3% from spot
ATM implied vol
54.3%
Nearest strike to spot
Skew (10% OTM)
-22.4%
Calls bid over puts
Call volume
47
Contracts, this expiry
Put volume
73
Contracts, this expiry
Heaviest call OI
80.00
25 contracts
Heaviest put OI
70.00
50 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
Outpatient & Specialty Care Stocks Q2 Teardown: U.S. Physical Therapy (NYSE:USPH) Vs The Rest
StockStory · 3d ago
US Physical Therapy Names Nchacha Etta as Chief Financial Officer
MT Newswires · 8d ago
U.S. Physical Therapy Announces CFO
Business Wire · 8d ago
USPH (USPH) Q2 2026 Earnings Call Transcript
Motley Fool · 9d ago
1 Russell 2000 Stock Worth Investigating and 2 We Brush Off
StockStory · 10d ago
Barrington Adjusts PT on U.S. Physical Therapy to $98 From $90, Maintains Outperform Rating
MT Newswires · 12d ago
U.S. Physical Therapy Q2 Earnings Call Highlights
MarketBeat · 13d ago
U.S. Physical Therapy (USPH): Return Expectations Tempered Despite Solid Execution
Insider Monkey · 15d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.